Previous Article | Next Article ![]()
Mol. Cell. Biol., Dec 1997, 6940-6947, Vol 17, No. 12
H Imataka and N Sonenberg
Mammalian translation initiation factor 4F (eIF4F) consists of three
subunits, eIF4A, eIF4E, and eIF4G. eIF4G interacts directly with both eIF4A
and eIF4E. The binding site for eIF4E is contained in the amino- terminal
third of eIF4G, while the binding site for eIF4A was mapped to the
carboxy-terminal third of the molecule. Here we show that human eIF4G
possesses two separate eIF4A binding domains in the middle third (amino
acids [aa] 478 to 883) and carboxy-terminal third (aa 884 to 1404) of the
molecule. The amino acid sequence of the middle portion of eIF4G is well
conserved between yeasts and humans. We show that mutations of conserved
amino acid stretches in the middle domain abolish or reduce eIF4A binding
as well as eIF3 binding. In addition, a separate and nonoverlapping eIF4A
binding domain exists in the carboxy- terminal third (aa 1045 to 1404) of
eIF4G, which is not present in yeast. The C-terminal two-thirds region (aa
457 to 1404) of eIF4G, containing both eIF4A binding sites, is required for
stimulating translation. Neither one of the eIF4A binding domains alone
activates translation. In contrast to eIF4G, human p97, a translation
inhibitor with homology to eIF4G, binds eIF4A only through the
amino-terminal proximal region, which is homologous to the middle domain of
eIF4G.
Copyright © 1997, American Society for Microbiology
Human eukaryotic translation initiation factor 4G (eIF4G) possesses two separate and independent binding sites for eIF4A
Department of Biochemistry and McGill Cancer Centre, McGill University, Montreal, Quebec, Canada.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|